Forest Baskett has an estimated net worth of $4.83 Billion. This is based on reported shares across multiple companies, which include Cloudflare, Inc., OPOWER, INC., TriVascular Technologies, Inc., SUPERNUS PHARMACEUTICALS INC, Zosano Pharma Corp, Nightstar Therapeutics plc, Tintri, Inc., TREVENA INC, PhaseBio Pharmaceuticals Inc, PROTEOSTASIS THERAPEUTICS, INC., ARDELYX, INC., Galera Therapeutics, Inc., Ra Pharmaceuticals, Inc., CHANNELADVISOR CORP, Liquidia Technologies Inc, HEMOSENSE INC, Oyster Point Pharma, Inc., Mersana Therapeutics, Inc., Sprout Social, Inc., GLYCOMIMETICS INC, Casper Sleep Inc., Berkshire Grey, Inc., Reneo Pharmaceuticals, Inc., Arcellx, Inc., Sagimet Biosciences Inc., BuzzFeed, Inc., AMICUS THERAPEUTICS INC, IonQ, Inc., MINERVA SURGICAL INC, IMARA Inc., ZeroFox Holdings, Inc., Senti Biosciences, Inc., XOOM Corp, SYNLOGIC, INC., CHAMPIONS ONCOLOGY, INC., Surface Oncology, Inc., Marker Therapeutics, Inc., Desktop Metal, Inc., RHYTHM PHARMACEUTICALS, INC., Dermira, Inc., Cascadian Therapeutics, Inc., Workday, Inc., Care.com Inc, Millennial Media Inc., AEROHIVE NETWORKS, INC, Echo Global Logistics, Inc., FUSION-IO, INC., MULESOFT, INC, ARYx Therapeutics, Inc., PEPLIN INC, HYPERION THERAPEUTICS INC, INNERWORKINGS INC, Robinhood Markets, Inc., Elastic N.V., Nkarta, Inc., NeueHealth, Inc., Verona Pharma plc, Monte Rosa Therapeutics, Inc., Groupon, Inc., AVEO PHARMACEUTICALS, INC., APPIAN CORP, Clovis Oncology, Inc., Mirum Pharmaceuticals, Inc., Adaptimmune Therapeutics PLC, BOX INC, Coursera, Inc., Loxo Oncology, Inc., GENOCEA BIOSCIENCES, INC., Metacrine, Inc., Inozyme Pharma, Inc., Millendo Therapeutics, Inc., TESARO, Inc., Eargo, Inc., Savara Inc, Trevi Therapeutics, Inc., Tracon Pharmaceuticals, Inc., Annexon, Inc., Epizyme, Inc., SUNESIS PHARMACEUTICALS INC, Akouos, Inc., Black Diamond Therapeutics, Inc., Arsanis, Inc., Cerecor Inc., Roka BioScience, Inc., Regulus Therapeutics Inc., ARCA biopharma, Inc., Omthera Pharmaceuticals, Inc., Tableau Software Inc, Strongbridge Biopharma plc, CVENT INC, Achaogen Inc, ATHEROS COMMUNICATIONS INC, AUDIENCE INC, INTERLEUKIN GENETICS INC, Korro Bio, Inc., MBX Biosciences, Inc., and SpyGlass Pharma, Inc..

2018 was Forest Baskett's most active year for acquiring shares with 75 total transactions. Forest Baskett's most active month to acquire stocks was the month of May. 2020 was Forest Baskett's most active year for disposing of shares, totalling 85 transactions. Forest Baskett's most active month to dispose stocks was the month of May. 2022 saw Forest Baskett paying a total of $146,449,993.20 for 14,474,870 shares, this is the most they've acquired in one year. In 2019 Forest Baskett cashed out on 145,573,724 shares for a total of $954,668,588.20, their largest year based on trade value.